CANCER LEADERSHIP COUNCIL
CLC
comments on alternative payment systems
(November 17, 2015)
November
17, 2015
Andy Slavitt
Acting Administrator
Centers for Medicare & Medicaid Services
Department of Health and Human Services
Hubert H. Humphrey Building
200 Independence Avenue, SW
Washington, DC 20201
RE:
CMS-3321-NC, Request for Information Regarding
Implementation of the Merit-Based Incentive Payment System,
Promotion of Alternative Payment Models, and Incentive Payments
for Participation in Eligible Alternative Payment Models
Dear Mr. Slavitt:
The undersigned organizations represent cancer patients,
physicians, and researchers who support health care payment and
delivery reforms that will foster patient-centered cancer
care. We appreciate the opportunity to respond to the
Request for Information regarding the Merit-Based Incentive
Payment System and Alternative Payment Models. We look
forward to ongoing interaction with the Centers for Medicare and
Medicaid Services (CMS) during the process of physician payment
transformation that is outlined in the Medicare Access and CHIP
Reauthorization Act of 2015 (MACRA).
The comments below focus on two of the performance categories in
the Merit-Based Incentive Payment System (MIPA) and recommend an
Alternative Payment System that would ensure the delivery of
high-quality survivorship care to Medicare beneficiaries who are
cancer survivors. We provide specific feedback
on the measures and activities related to two of the four
performance categories under the MIPS.
Resource Use Performance Category
MACRA requires the Secretary to evaluate costs – or resource use
– based on a composite of appropriate measures of
costs. The methodology for evaluating resource use
is defined in MACRA, and the experience of CMS in the
Value-Based Payment Modifier (VM) system is
assumed to be relevant to this evaluation. The Request for
Information seeks comment on the development of a resource use
measure that, in addition to measuring overall costs of care,
would evaluate harmful or over-used services, including those
identified in the Choosing Wisely initiative.
Instead of a resource measure that would focus only on potential
over-utilization, we urge development of a resource measure for
cancer care delivery that would focus on appropriate, or
targeted, utilization of services. Cancer therapies are
increasingly targeted according to the molecular profile of a
patient’s cancer. Not all cancer treatments are targeted
medicines, of course. However, for those medicines that
developed for specific targets, there are too many failures
related to their delivery.
If patients do not undergo proper molecular diagnosis, they may
not receive medicines that would provide benefit. On the
other hand, patients who will not benefit from targeted
therapies may receive them inappropriately because they are not
properly diagnosed. In this case, there is
over-utilization of the targeted therapy, but mostly
importantly, the patient is not receiving the treatment best for
him or her. These delivery failures result in improper
utilization – both overutilization and underutilization.
We urge that a measure for proper molecular diagnosis and
subsequent use of targeted cancer therapies be incorporated in
the resource use performance category. Such an
effort is necessary for proper resource utilization, including
of new targeted cancer therapies, and to ensure that patients
receive the right treatment at the right time. We
understand that diagnostic tests are not available for all
therapies and that not all cancer therapies are
“targeted.” However, accurate diagnosis, including
molecular diagnosis where appropriate, should guide treatment
decisions.
Clinical Practice Improvement Activities Performance
Category
The term “clinical practice improvement” is defined in the
Social Security Act, as amended by MACRA, as “an activity that
relevant eligible professional organizations and other relevant
stakeholders identify as improving clinical practice or care
delivery and that the Secretary determines, when effectively
executed, is likely to result in improved outcomes.”
Moreover, the Act specifies that the measures and activities for
the clinical practice improvement activities performance
category must include at least these efforts: expanded
practice access, population management, care coordination,
beneficiary engagement, patient safety and practice assessment,
and participation in an alternative practice model.
Our comments focus on defining a subcategory of clinical
practice improvement activity, which might most logically be
classified under the “care coordination” performance
activity. We propose a treatment planning and coordination
activity subcategory that would include these elements: 1)
shared decision-making that considers treatment goals and
outlines all elements of active treatment and symptom management
in a written plan, 2) coordination of all elements of
multi-disciplinary cancer care, and 3) appropriate management of
the side effects of treatment and symptoms of
cancer.
Cancer care that is planned according to the patient’s
preferences and that coordinates active treatment and symptom
management from the beginning of treatment holds the promise of
boosting patient satisfaction with care, improving outcomes, and
enhancing the appropriate utilization of cancer care resources.1
If a practice undertakes this sort of treatment planning and
coordination, the process of practice transformation will be
accelerated, quality of care and patient satisfaction will be
improved, and appropriate resource utilization will be
encouraged.
The “subcategory activity” of treatment planning and
coordination can be reported by cancer care providers through a
qualified registry or electronic health record. We also
propose that a Consumer Assessment of Healthcare Providers and
Systems (CAHPS) item set focusing on treatment planning and
coordination be developed and utilized as part of the reporting
and assessment of clinical practice improvement activities and
specifically treatment planning and coordination. There
exists a CAHPS item set that gathers information on patient
experience in a patient-centered medical home; a modification of
that item set might be useful in assessing cancer care provider
implementation of the activities of treatment planning and
coordination.
The Request for Information seeks comment on the benchmark for
assessing performance on clinical practice improvement
activities. We urge CMS to develop a MIPS performance
benchmark for clinical practice improvement activities that will
not penalize those oncology practices that have already made
progress toward practice transformation through clinical
practice improvement. These would include oncology
practices that are already testing the patient-centered medical
home concept and others that are undertaking practice
improvements. These practices would include certain
participants in the American Society of Clinical Oncology
Quality Oncology Practice Initiative.
An Alternative Payment Model for Cancer Survivorship Care
Congress anticipated that MACRA would encourage the development
of alternative payment models by medical professionals, their
professional societies, and health systems. In fact, the
law describes the new payment models as “physician-focused,” and
requires that they be evaluated for implementation by the
“Physician-focused Payment Model Technical Advisory
Committee.” We propose a patient-focused payment and care
model that could be implemented under the framework of a
“physician-focused” system.
We recommend an alternative payment system for the delivery of
comprehensive cancer survivorship care. Individuals who
have been diagnosed with cancer and received treatment that
might include surgery, radiation, and chemotherapy are often
“lost in transition” as they move from active treatment to
long-term survivorship.2
In a 2006 report on the problems of cancer survivors, the
National Cancer Policy Board of the Institute of Medicine
identified the essential components of survivorship care.
These are:
- Prevention of
recurrent and new cancers and the prevention of other late
effects;
- Surveillance
for cancer spread, recurrence, and second cancers, as well
as the assessment of medical and psychosocial late effects;
- Intervention
for the consequences of cancer and its treatment.
These consequences might include lymphedema and sexual
dysfunction, pain, fatigue, depression, psychological
distress, and concerns related to employment, insurance, and
disability; and
- Coordination
between primary care providers and specialists to ensure
that survivors’ health needs, as described above, are
addressed.3
An alternative
payment system including providers caring for cancer survivors
holds great promise for addressing the serious and complex
chronic health care needs of many cancer survivors and fairly
compensating cancer care professionals providing this complex
care. The need for a system of this sort is clear.
There will be a 30% increase in the number of cancer survivors
by 2022 and a 45% increase in cancer incidence by 2030.
Approximately 53% of cancer diagnoses were in individuals 65 and
older in 2012, and 59% of cancer survivors were 65 years or
older in 2012.4
The burden of cancer and cancer survivorship on individuals,
families, and the nation is significant. Medicare
beneficiaries and the Medicare program bear significant
financial responsibility for the cancer care system simply
because of the incidence of cancer and the number of cancer
survivors in this population. An alternative payment
system might focus initially on Medicare beneficiaries who are
cancer survivors and be expanded to other populations of cancer
survivors.
We anticipate challenges associated with the development of an
alternative payment system that would focus on a specific
population, but its potential benefits argue for its
consideration as a range of alternative payment systems are
developed and implemented. We encourage CMS to entertain
proposals for cancer survivorship care and to take an additional
step by providing guidance that would address ways to combine a
patient-centered payment system with the physician-focused
payment reform structure.
We appreciate the opportunity to offer comments on MIPS and on
alternative payment systems and look forward to additional
discussion with CMS about ensuring a patient focus in these
payment reform efforts.
Sincerely,
Cancer Leadership Council
American Society for Radiation Oncology
CancerCare
Cancer Support Community
The Children's Cause for Cancer Advocacy
Fight Colorectal Cancer
International Myeloma Foundation
The Leukemia & Lymphoma Society
LIVESTRONG Foundation
Lymphoma Research Foundation
Multiple Myeloma Research Foundation
National Coalition for Cancer Survivorship
National Patient Advocate Foundation
Ovarian Cancer National Alliance
Pancreatic Cancer Action Network
Prevent Cancer Foundation
Susan G. Komen
Us TOO International Prostate Cancer Education and Support
Network
1 Temel JS, Greer JA, Muzikansky A, et al.
Early Palliative Care for Patients with Metastatic Non-Small-Cell
Lung Cancer. N Engl J Med. August 19, 2010.
2 Hewitt M, Greenfield S, and Stovall E.
From Cancer Patient to Cancer Survivor: Lost in Transition,
National Cancer Policy Board of Institute of Medicine, 2006.
3 Hewitt M, et al. From Cancer Patient to
Cancer Survivor. 2006.
4 Levitt LA, Balogh EP, Nass SJ, and Ganz
PA. Delivering High-Quality Cancer Care: Charting a New
Course for a System in Crisis. Institute of Medicine, 2013.